Tag Archives: Cancer News

Alternative Cancer Treatment, Cancer Care Tips, Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer, Living with Cancer, News

Could Where You Live in Your Time Zone Affect Your Cancer Risk?

Does Your Time Zone Impact Cancer?
Tired When You Get Up? Could Your Time Zone Impact Cancer?

While the hour may be the same throughout a time zone, the degrees of sunlight and darkness are not. A recent study suggests that this quirk of nature may be linked to an increased cancer risk.

When Day Becomes Night

A research team at the National Cancer Institute was inspired by previous research showing slightly higher cancer risk among people who work the night shift. This finding was attributed to circadian disruption, which is a change in the body’s biological clock.

Shift workers experience extreme circadian disruption owing to almost complete reversal of day and night. The NCI researchers set out to see if the increased risk of cancer applied to minor disruptions in the body’s natural rhythms, referred to as social jet lag.

The most common example of social jet lag is rising at different times on work days and weekends, but the phenomenon also occurs with people living on either end of a time zone, where light and dark come at different times.

Effects of Social Jet Lag on Cancer Risk

After reviewing data from 4 million white adults who had been diagnosed with cancer, the NCI team found each five degrees of longitude toward the west resulted in an increased risk of three percent for men and four percent for women. Greater risk was also found specifically for breast cancer, prostate cancer and uterine cancer.

Issels®: Leading the Way in Immunotherapy for Cancer

Our Issels® clinic has been in the forefront of state-of-the-art immunotherapy for cancer treatments. Contact us to learn more about our personally tailored integrative programs.

Cancer Research, Cancer Treatment, Immunotherapy for Cancer, Living with Cancer

In the News: Low Dose Aspirin Reduces Cancer Death Risk

2 Comments
Low Dose Aspirin Therapy
Low Dose Aspirin Therapy May Reduce Cancer Death Risk

Could aspirin become a powerful weapon in immunotherapy for cancer? Researchers have found evidence that a daily regimen of low-dose aspirin may lower the mortality rate of cancer patients.

An Aspirin a Day

Aspirin is an anti-inflammatory drug that has been used as a pain reliever since the days of ancient Egyptians. In early April, attendees at the American Association for Cancer Research meeting in Washington, D.C. learned why aspirin also holds promise for treating cancer patients.

Yin Cao, an instructor at Massachusetts General Hospital and Harvard Medical School, reviewed data from long-term health studies involving both men and women. While the overall risk of death was lower for individuals who took a daily dose of aspirin, Cao found that the risk of dying from cancer was 7 percent lower in women and 15 percent lower in men.

The connection was most dramatic with colorectal cancer, as women had a 31 percent lower risk and men’s risk was 30 percent lower. Significant reductions were also found among women with breast cancer and men with prostate or lung cancer.

Is Aspirin Treatment for Everyone?

Despite the encouraging results, Cao offered a note of caution for anyone considering this course of medication. Aspirin increases risk of ulcers and gastrointestinal bleeding, so Cao emphasized the importance of consulting with your doctor before undertaking a daily program.

Issels®: Fighting Cancer and Its Causes

Our immunotherapy for cancer treatment programs go beyond eliminating tumors to helping your immune system regain its natural defense mechanisms. Contact us to learn more about cancer vaccines and our other personally tailored integrative programs.

Cancer Research, Immuno-Oncology, Immunotherapy for Cancer

Genetic Advances Made in Prostate Cancer Identification

Prostate cancer affects approximately 15 percent of males in their lifetime, and is second only to skin cancer. Recent identification of an overactive gene that accelerates prostate cancer could lead to development of a more effective treatment.

Prostate Cancer Evolves Beyond Drugs

Most prostate tumors are caused by a form of cancer called adenocarcinoma. In advanced stages, adenocarcinoma is treated with drugs that block androgens, the male hormones that fuel the tumor. Unfortunately, the tumors have evolved into a more aggressive, androgen-resistant form called neuroendocrine prostate cancer.

Prostate Cancer Identification
Prostate Cancer Identification

A cross-disciplinary team supported by the Prostate Cancer Foundation discovered a gene known as N-Myc that appears to be the driver behind the change to the more aggressive form. While N-Myc is not usually found in prostate cancer, it has been known to occur in other forms such as neuroblastoma, a rare cancer of the nervous system found in children.

A Pathway to New Treatment Methods

When N-Myc goes into overdrive, it teams up with a protein called EZH2 to block the tumor’s androgen signaling and “flips the switch” on the molecular program that leads to the more aggressive neuroendocrine form. Dr. Jonathan W. Simons, president and CEO of the Prostate Cancer Foundation, calls this a “game-changing” discovery that can enable development of more successful treatments.

Personalized, Non-Toxic Treatments for Prostate Cancer

Issels® offers a wide range of Immunotherapy for Cancer protocols, including vaccines and NK cells that have been used to treat patients with prostate cancer, melanoma, leukemia and all other forms. Contact us today to find out how Immunotherapy for Cancer at Issels® can help you or your loved one.

Cancer Research, Immunotherapy, Immunotherapy for Cancer, News

Immunotherapy is the Hot Buzz in the World of Cancer Research Publications

Could Immunotherapy Be Your Miracle Treatment?
Cancer Immunothereapy in the News

Thanks to rapid and effective developments, immunotherapy for cancer continues to be a hot topic in the medical community. A recent analysis shows the explosive growth of this subject in academic and industrial publications.

Immunotherapy for Cancer in the News

Results of the analysis conducted by Drs. Enal Razvi and Gary Oosta were published in Genetic Engineering & Biotechnology News. Data was based on publications in the broad space of cancer immunology, which have seen exponential growth from zero in the early ’70s to more than 600 in the past year.

While there has been a clear increase in quantity, what about qualitative measures? A word cloud corresponding to titles and abstracts shows that the major areas of focus are “cancer,” “immunotherapy,” “cells,” “immune” and “tumor.”

Drilling down to find the key components of these publications, the most commonly mentioned one is “dendritic cells,” which play a vital role in initiating the immune response. “Cell death” (apoptosis) has generated 33 percent annual growth.

What Does the Future Hold?

Drs. Razvi and Oosta drew the following conclusions:

  • Understanding in vivo mechanisms and pathways driving immunological cascades is crucial for continued progress.
  • Companies will continue clinical trials, both individually and in collaboration with others.
  • Immunotherapy for cancer will eventually use biomarkers to identify which populations and sub-populations are the optimum candidates for specific treatments.

Individualized Blueprints for Immunotherapy

At Issels®, our integrative therapies are personalized based on each patient’s lifestyle and genetic makeup as well as the tumor microenvironment. Contact us today to hear success stories from patients of all ages who have dealt with leukemia, melanoma and other forms of cancer.

Alternative Cancer Treatment, Cancer Research, News

Stanford Scientists Research New Ways to Target Cancer

New Approaches to Cancer Bring New Perspectives to Potentially Solving this Disease.
New Approaches to Cancer Bring New Perspectives to Potentially Solving this Disease.

Cancer treatment has come a long way in the last 20 years. From immunotherapy for cancer to synthesized protein antibodies, cancer patients now have a variety of options to choose from when it comes to treatment in early or late stages.

Stanford Study Shows Promise

One of the major drawbacks of chemotherapy is the range of side effects that come with a dose strong enough to take care of a tumor. Stanford researchers have found a way to bind a synthetic protein to specific molecules in the lining of certain cells, allowing them to easily pass through without needing to be delivered via the blood stream.

Since particularly dense tumors are difficult to treat due to their lack of blood flow, many chemotherapy drugs need to be administered in high doses to get the desired effect.

The Importance of Synthetic Protein Antibodies

Much like a sponge, a tumor might absorb these special protein antibodies just by contact, leading to the saturation of the chemical within the tumor. This can cause the cancer cells to die off and the tumor to shrink, possibly eliminating the cancer causing cells completely.

All of this is done without the harmful effects of large doses of chemotherapy drugs. While these synthetic protein antibodies show promise, they could still be a few years away from the mass market.

It’s good to know that immunotherapy for cancer already exists even for late-stage patients, and new treatments are being developed by researchers to improve life expectancy and quality of life. If you would like to receive more information, get in touch with us today.

Cancer Research, News

Watch that Powder, Talc use May Cause Uterine Cancer

Talcum Powder Linked to Uterine Cancer
Talcum Powder Linked to Uterine Cancer

Experts have warned about the use of talcum powder for years, but these claims have been a source of controversy. Researchers have recently put that controversy to rest by publishing the results of a study linking talcum powder to uterine cancer.

Researchers at Brigham and Women’s Hospital found that using talcum powder in the genital area can lead to a higher risk of ovarian cancer in women. In fact, this cancer risk was shown to be about one-third higher in those who use talcum powder. Scientists who participated in this study are calling for manufacturers to place labels on talcum powder products so women who use them are informed of these risks. Talcum powder is believed to raise the risk of ovarian cancer if it gets into the vagina and reaches the upper genital tract.

This study was published shortly after a jury ordered manufacturer Johnson & Johnson to pay the family of a woman who died of uterine cancer $72 million. The family claims that the woman’s use of Johnson & Johnson’s talcum powder products led to her developing this deadly form of cancer.

The Brigham and Women’s Hospital study provides further evidence that there is a link between the use of talcum powder and an increased risk of ovarian cancer. While scientists state that more research is needed, many caution against using this type of powder, especially in the genital area.

Those who are interested in learning more about non-toxic treatments for uterine cancer should contact Issels®. We offer immunotherapy and other types of safe non-toxic treatments for many types of cancer.